

# Brian S Gerstenberger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5531696/publications.pdf>

Version: 2024-02-01

8  
papers

304  
citations

1478505

6  
h-index

1588992

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

402  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( <i>S</i> )-2,2-Difluorocyclopropyl)(( <i>R</i> ,5 <i>S</i> )-3-(2-((1-methyl-1 <i>H</i> -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.1.0]hexan-6-yl)pyrimidin-2-amine (PF-06700841). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8597-8612.	4.6	87
2	One-Pot Synthesis of <i>N</i> -Arylpyrazoles from Arylhalides. <i>Organic Letters</i> , 2009, 11, 2097-2100.	4.6	87
3	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13561-13577.	6.4	45
4	One-pot copper-catalyzed synthesis of <i>N</i> -functionalized pyrazoles from boronic acids. <i>Tetrahedron Letters</i> , 2010, 51, 5005-5008.	1.4	16
5	A direct copper-catalyzed route to pyrrolo-fused heterocycles from boronic acids. <i>Tetrahedron Letters</i> , 2012, 53, 564-569.	1.4	14
6	Synthesis of Chiral Azabicycles from Pyroglutaminols. <i>Organic Letters</i> , 2016, 18, 5748-5751.	4.6	11
7	Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115481.	3.0	10
8	Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. <i>Scientific Reports</i> , 2020, 10, 8974.	3.3	5